Kelly Pike

Academic title(s): 

Head of Translational Sciences and Scientific Affairs at Ventus Therapeutics

Kelly Pike
Contact Information

7150 Frédérick-Banting
Montréal, QC H4S 2A1

Email address: 
kpike [at]
Adjunct Members
Graduate supervision: 

Dr. Pike is not offering graduate supervision. 


Kelly Pike is the Head of Translational Sciences and Scientific Affairs at Ventus Therapeutics (, bringing an expertise in molecular and cellular immunology. Prior to Ventus, Kelly held roles in small molecule drug development at Inception Sciences and Kanyr Pharma, spanning auto-inflammation and adoptive immunotherapy. She is also an Adjunct Professor in the Department of Microbiology and Immunology at McGill University, lecturing on the challenges of drug discovery for inflammatory diseases. Kelly has a BSc in Microbiology and Immunology from McGill University and a Ph.D. in Immunology from the University of Toronto. She conducted postdoctoral studies in the laboratory of Dr. Tony Pawson at the Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, investigating the molecular mechanisms of signal transduction in the immune system.

Selected publications: 
  • Pike KA, Tremblay ML.TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies. Cytokine. 2016 Jun;82:52-7.
  • Pike KA, Hutchins AP, Vinette V, Théberge JF, Sabbagh L, Tremblay ML, Miranda-Saavedra D. Protein tyrosine phosphatase 1B is a regulator of the interleukin-10-induced transcriptional program in macrophages. Sci Signal. 2014 May 6;7(324):ra43.
  • Pike KA, Tremblay ML. Regulating naïve and memory CD8 T cell homeostasis--a role for protein tyrosine phosphatases. FEBS J. 2013 Jan;280(2):432-44.
  • Pike KA, Kulkarni S, Pawson T. Immature T-cell clustering and efficient differentiation require the polarity protein Scribble. Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1116-21.
Back to top